Truist raised the firm’s price target on Globus Medical (GMED) to $105 from $93 and keeps a Buy rating on the shares. The firm cites multiple expansion in the comp group for the price target update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical’s Earnings Call Highlights Robust Growth
- Globus Medical rises 33.2%
- Midday Fly By: Musk pay plan approved, ‘GTA VI’ delayed
- Globus Medical price target raised to $92 from $88 at RBC Capital
- Globus Medical: Strong Q3 Performance and Raised Guidance, But Long-term Growth Concerns Justify Hold Rating